Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Ramipril; Telmisartan

Criteria

Inclusion Criteria:

• Male and female patients >=18 years of age with Stage I or II hypertension defined as:

• a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg Main

Exclusion Criteria:

• Pregnant

• breast-feeding

• unwilling to use birth control during the study

• secondary hypertension

• SBP>=180 mmHg

• DBP>=120 mmHg

• severe renal dysfunction

• hepatic insufficiency

• stroke within the last 6 months

• myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months

• unstable or uncontrolled diabetes

• history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.